TY - JOUR
T1 - Egfl7 Represses the Vasculogenic Potential of Human Endothelial Progenitor Cells
AU - d’Audigier, Clément
AU - Susen, Sophie
AU - Blandinieres, Adeline
AU - Mattot, Virginie
AU - Saubamea, Bruno
AU - Rossi, Elisa
AU - Nevo, Nathalie
AU - Lecourt, Séverine
AU - Guerin, Coralie L.
AU - Dizier, Blandine
AU - Gendron, Nicolas
AU - Caetano, Bertrand
AU - Gaussem, Pascale
AU - Soncin, Fabrice
AU - Smadja, David M.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media, LLC.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Egfl7 (VE-statin) is a secreted protein mostly specific to the endothelial lineage during development and in the adult and which expression is enhanced during angiogenesis. Egfl7 involvement in human postnatal vasculogenesis remains unresolved yet. Our aim was to assess Egfl7 expression in several angiogenic cell types originating from human bone marrow, peripheral blood, or cord blood. We found that only endothelial colony forming cells (ECFC), which are currently considered as the genuine endothelial precursor cells, expressed large amounts of Egfl7. In order to assess its potential roles in ECFC, Egfl7 was repressed in ECFC by RNA interference and ECFC angiogenic capacities were tested in vitro and in vivo. Cell proliferation, differentiation, and migration were significantly improved when Egfl7 was repressed in ECFC in vitro, whereas miR-126-3p levels remained unchanged. In vivo, repression of Egfl7 in ECFC significantly improved post-ischemic revascularization in a model of mouse hind-limb ischemia. In conclusion, ECFC are the sole postnatal angiogenic cells which express large amounts of Egfl7 and whose angiogenic properties are repressed by this factor. Thus, Egfl7 inhibition may be considered as a therapeutic option to improve ECFC-mediated postnatal vasculogenesis and to optimize in vitro ECFC expansion in order to develop an optimized cell therapy approach.
AB - Egfl7 (VE-statin) is a secreted protein mostly specific to the endothelial lineage during development and in the adult and which expression is enhanced during angiogenesis. Egfl7 involvement in human postnatal vasculogenesis remains unresolved yet. Our aim was to assess Egfl7 expression in several angiogenic cell types originating from human bone marrow, peripheral blood, or cord blood. We found that only endothelial colony forming cells (ECFC), which are currently considered as the genuine endothelial precursor cells, expressed large amounts of Egfl7. In order to assess its potential roles in ECFC, Egfl7 was repressed in ECFC by RNA interference and ECFC angiogenic capacities were tested in vitro and in vivo. Cell proliferation, differentiation, and migration were significantly improved when Egfl7 was repressed in ECFC in vitro, whereas miR-126-3p levels remained unchanged. In vivo, repression of Egfl7 in ECFC significantly improved post-ischemic revascularization in a model of mouse hind-limb ischemia. In conclusion, ECFC are the sole postnatal angiogenic cells which express large amounts of Egfl7 and whose angiogenic properties are repressed by this factor. Thus, Egfl7 inhibition may be considered as a therapeutic option to improve ECFC-mediated postnatal vasculogenesis and to optimize in vitro ECFC expansion in order to develop an optimized cell therapy approach.
KW - Angiogenesis
KW - ECFC
KW - Egfl7
KW - Endothelial colony forming cells
KW - Endothelial progenitor cells
KW - Ischemia
UR - http://www.scopus.com/inward/record.url?scp=85030562165&partnerID=8YFLogxK
U2 - 10.1007/s12015-017-9775-8
DO - 10.1007/s12015-017-9775-8
M3 - Article
C2 - 28980146
AN - SCOPUS:85030562165
SN - 1550-8943
VL - 14
SP - 82
EP - 91
JO - Stem Cell Reviews and Reports
JF - Stem Cell Reviews and Reports
IS - 1
ER -